These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15550587)

  • 1. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
    Mollee P; Arthur C; Hughes T; Januszewicz H; Grigg A; Bradstock K; Wolf M; Gibson J; Schwarer AP; Spencer A; Browett P; Hawkins T; Seldon M; Herrmann R; Watson A; Seymour JF; Martin N; Shina S; Low C; Wright S; Rodwell R; Coulston J; Morton J; Blacklock H; Taylor D; Taylor KM
    Ann Oncol; 2004 Dec; 15(12):1810-5. PubMed ID: 15550587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
    Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall JF; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque JP; Delain M; Harousseau JL; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
    Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.
    Kühr T; Eisterer W; Apfelbeck U; Linkesch W; Bechter O; Zabernigg A; Geissler K; Barbieri G; Duba C; Gastl G; Thaler J
    Leuk Res; 2000 Jul; 24(7):583-7. PubMed ID: 10867132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous oral cytarabine ocfosfate with interferon-alpha-2b for patients with newly diagnosed chronic myeloid leukaemia: a pilot study.
    del Cañizo MC; Fisac MP; Galende J; Hurtado JA; Moro MJ; Rodriguez JA; Rivas JM; Tabernero MD;
    Br J Haematol; 2001 Dec; 115(3):541-4. PubMed ID: 11736933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.
    Gotoh A; Miyazawa K; Uchida Y; Sashida G; Kawakubo K; Kuriyama Y; Ohyashiki K
    Int J Hematol; 2002 Feb; 75(2):191-4. PubMed ID: 11939268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
    Cervantes F; Sureda A; Hernández-Boluda JC; Martino R; Brunet S; Borrego D; Antich JL; Montserrat E
    Haematologica; 2001 Dec; 86(12):1281-6. PubMed ID: 11726320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
    Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
    Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AraC-based pharmacotherapy of chronic myeloid leukaemia.
    Reiter A; Hochhaus A; Berger U; Kuhn C; Hehlmann R
    Expert Opin Pharmacother; 2001 Jul; 2(7):1129-35. PubMed ID: 11583064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
    Millot F; Guilhot J; Nelken B; Leblanc T; Leverger G; Bernard F; Gandemer V; Béhard C; Berger C; Cornu G; Duchène S; Guilhot F
    Pediatr Blood Cancer; 2006 Oct; 47(5):555-9. PubMed ID: 16317737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia.
    Kalambokis G; Stefanou D; Arkoumani E; Kitsanou M; Bourantas K; V Tsianos E
    Eur J Haematol; 2004 Jul; 73(1):67-70. PubMed ID: 15182341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
    Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
    N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia.
    Rosti G; Bonifazi F; Trabacchi E; De Vivo A; Bassi S; Martinelli G; Testoni N; Russo D; Baccarani M
    Leukemia; 2003 Mar; 17(3):554-9. PubMed ID: 12646944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
    Braess J; Freund M; Hanauske A; Heil G; Kaufmann C; Kern W; Schüssler M; Hiddemann W; Schleyer E
    Leukemia; 1998 Oct; 12(10):1618-26. PubMed ID: 9766508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
    Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
    Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia.
    Lindauer M; Domkin D; Döhner H; Kolb HJ; Neubauer A; Huhn D; Kreiter H; Koch B; Huber C; Aulitzky W; Fischer T
    Br J Haematol; 1999 Sep; 106(4):1013-9. PubMed ID: 10520005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.